July 16, 2025 — The American Heart Association has appointed two leading health and science leaders, Jennifer Ashton, M.D., M.S. and Joseph Woo, M.D., FAHA, to its volunteer Board of Directors, effective July 1, 2025.

Ashton and Woo bring clinical leadership, health media influence and scientific innovation to the Association as it enters its second century, intensifying its efforts to change the future of health and improve cardiovascular and cerebrovascular health outcomes.

July 11, 2025 — Heartflow, Inc. has announced that its Heartflow Plaque Analysis will be included in updated cardiac imaging guidelines by radiology benefit manager EviCore, which provides coverage guidelines to leading commercial health insurers.

July 9, 2025 — Cleerly, a leader in advanced cardiovascular imaging, will be presenting new research at the Society of Cardiovascular Computed Tomography (SCCT) Annual Meeting 2025. The conference will take place July 17-20, 2025, at the Palais des Congrès de Montréal in Montreal, Canada. This annual event brings together leading cardiovascular imaging specialists, researchers, and technology innovators from around the world to share the latest advances in cardiovascular computed tomography.

July 10, 2025 — Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, will be featured along with its PlaqueIQ image analysis software at the 20th Annual Meeting of the Society of Cardiovascular Computed Tomography (SCCT 2025), taking place July 17-20 at Palais des Congrès de Montréal.

July 15, 2025 — Vivalink, a provider of digital healthcare solutions, has announced its wearable ECG monitor is supporting research at Brigham and Women’s Hospital in Boston aimed at understanding and improving detection of postoperative atrial fibrillation (poAF).

July 14, 2025  –  Johnson & Johnson MedTech has announced U.S. Food and Drug Administration (FDA) approval of an update to the Varipulse Platform’s irrigation flow rate, reflecting the company’s commitment to the evolution of pulsed field ablation (PFA) innovation following real-world clinical practice. 

July 14, 2025 — Bayer has announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA (finerenone) to treat patients with heart failure (HF) with left ventricular ejection fraction (LVEF) ≥40%,1 following the agency’s Priority Review of its supplemental New Drug Application (sNDA).

July 10, 2025 — On July 2, 2025, Centers for Medicare & Medicaid Services (CMS) issued a National Coverage Determination (NCD) that covers Abbott's FDA approved Transcatheter Edge-to-Edge Repair for Tricuspid Valve Regurgitation (T-TEER) for the treatment of symptomatic tricuspid regurgitation (TR) under Coverage with Evidence Development (CED), when furnished in accordance with the coverage criteria specified in the NCD.

July 1, 2025 — Stereotaxis, a provider of surgical robotics for minimally invasive endovascular intervention, has announced the publication of initial clinical results using the MAGiC catheter in the Journal of Interventional Cardiac Electrophysiology. Titled “First In‑Human Results of the MAGiC Robotic Magnetic Navigation Radiofrequency Ablation Catheter,” the publication is the first peer-reviewed literature supporting the efficacy and safety of Stereotaxis’ MAGiC catheter.

July 10, 2025 — A study led by scientists at King's College London has revealed how the physical orientation of the heart inside the chest dramatically influences the electrical signals captured in an electrocardiogram (ECG) — a discovery that could pave the way for more personalized and accurate heart diagnostics. 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now